Patients
Working toward real functional recovery for people with a central nervous system injury.
Spinal cord injury leads to a lifelong loss of motor and sensory function below the level of the lesion. For decades, the limited self-repair capacity of the human central nervous system has meant these deficits persist. NovaGo’s mission is to change that.
By blocking Nogo-A — a potent natural brake on nerve-fiber growth — our therapies aim to open a window for regeneration and meaningful functional recovery.
The clinical trial
The SPROUT Phase 1b study of NG004 is recruiting patients with acute spinal cord injury across four centres in Germany and two in Switzerland.
How it works
NG004 blocks and neutralizes Nogo-A, helping injured nerve fibers regrow and form new connections — aiding the spinal cord’s recovery.
Beyond spinal cord
The same regenerative principle underpins NovaGo’s preclinical programs in acute ischemic stroke and secondary progressive MS.